Castle Biosciences, Inc. Common Stock (CSTL) is a publicly traded Healthcare sector company. As of May 21, 2026, CSTL trades at $20.00 with a market cap of $585.97M and a P/E ratio of -23.44. CSTL moved +4.35% today. Year to date, CSTL is -48.64%; over the trailing twelve months it is +21.39%. Its 52-week range spans $14.59 to $44.28. Analyst consensus is strong buy with an average price target of $44.40. Rallies surfaces CSTL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Castle Biosciences Wins 2026 Genomics Innovation Award for AdvanceAD-Tx Test: Castle Biosciences' AdvanceAD-Tx test, a non-invasive gene expression profile analyzing 487 genes across 12 pathways, won the 2026 MedTech Breakthrough Award for genomics innovation—the fifth such award for the company. In validation, patients matching test-guided JAK inhibitor profiles achieved near-clear skin 5.5 times more often and 3.8 times faster.
| Metric | Value |
|---|---|
| Price | $20.00 |
| Market Cap | $585.97M |
| P/E Ratio | -23.44 |
| EPS | $-0.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $44.28 |
| 52-Week Low | $14.59 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $344.23M |
| Net Income | $-24.16M |
| Gross Margin | 79.37% |
5 analysts cover CSTL: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.40.